Table 3.

Summary of outcomes by agents

	Bleomycin		Ethanol		Sodium tetradecyl sulfate		Ethanolamine		Pingamycin
	% (95% CI)	P-value vs. bleomycin	% (95% CI)	P-value vs. bleomycin	% (95% CI)	P-value vs. bleomycin	% (95% CI)	P-value vs. bleomycin	% (95% CI)	P-value vs. bleomycin
Complete cure	66.1 (31.3–100.9)	Ref.	58.8 (39.8–77.9)	0.004	55.5 (36.1–74.9 )	0.005	78.3 (58.9–97.6)	<0.001	85.9 (72.7–99.2)	<0.001
Partial cure	24.5 (1.7–47.3)	Ref.	35.3 (19.1–51.5)	0.18	25.9 (13.1–38.6)	0.08	19.5 (2.1–37.0)	0.05	12.5 (1.0–24.0)	0.03
No benefit	12.9 (0.7–26.6)	Ref.	4.0 (1.2–6.8)	0.003	14.9 (4.3–25.4)	0.02	2.1 (0.2–4.4)	<0.001	2.6 (0.1–5.2)	<0.001
Improvement in QoL		Ref.	89.8 (76.4–3.2)		46.7 (22.4–71.0)		98.1 (94.5–100)
Patient satisfaction	94.3 (88.3–100.3)	Ref.	96.0 (92.5–99.6)	0.72	72.8 (63.6–81.9)	<0.001	76.5 (62.2–90.7)	0.02
Pulmonary complication	2.2 (0.0–5.4)	Ref.	1.5 (0.2–2.8)	1.00	2.4 (0.5–5.3)	0.38	2.0 (0.0–5.9)	1.00	0.8 (0.0–2.3)	1.00
Skin necrosis/scar	2.3 (1.0–5.7)	Ref.	1.4 (0.1–2.7)	0.69	2.1 (0.8–3.4)	0.71	2.0 (0.0–5.9)	1.00	0.8 (0.0–2.3)	0.35
Any permanent morbidity/mortality	2.2 (0.0–5.4)	Ref.	1.0 (0.1–2.1)	1.00	0.5 (0.1–1.2)	1.00	1.8 (0.0–4.8)	1.00	0.8 (0.0–2.3)	1.00
Local temporary complication	27.0 (5.4–59.4)	Ref.	30.0 (3.3–56.7)	0.61	44.0 (10.6–77.4)	<0.001	51.0 (24.7–26.6)	<0.001	36.2 (19.7–92.1)	0.45

CI, confidence interval; Ref., reference; QoL, quality of life.